Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Bmy crawled date : 2022 - 06 - 06 save search
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 0.0%
H: 3.42%
C: 2.33%
al101 asco
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
opdivo trial plus phase 3 nivolumab
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
treatment opdivo trial plus cancer phase 3 nivolumab
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.